[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-and-metabolic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-and-metabolic-syndrome":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100638671",false,"NCT07589322","Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs","Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study","COMPARE-AT","Inclusion Criteria:\n\n* Age 20-65 years.\n* BMI ≥27 kg\u002Fm² with metabolic syndrome (ATP III or IDF criteria).\n* Stable background medications (antihypertensives, statins, etc.) for ≥3 months.\n* Able and willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* History of diabetes; history of pancreatitis; personal\u002Ffamily history of medullary thyroid carcinoma or MEN2.\n* eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m², decompensated liver disease, NYHA class III-IV heart failure.\n* Recent (\\\u003C3 months) acute coronary syndrome, stroke, or coronary revascularization.\n* Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months.\n* Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy).","ALL","20 Years","65 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, open label, head to head clinical trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome (N=120, age 20-65, 1:1 randomization). Participants undergo deep phenotyping at baseline, 6 months, and 12 months, including DXA (regional fat, lean mass, and BMD), MRI PDFF (liver fat), 7 site skinfold thickness, grip strength, fasting biochemistry, and AI processed 12 lead ECGs. Centralized biobanking of serum, plasma, and PBMCs enables targeted and discovery multi omic analyses.",[27],"Obesity and Metabolic Syndrome",[29,30,31,32,33],"tirzepatide","semaglutide","obesity","metabolic syndrome","multi omic","RECRUITING","2026-05-10",{"date":37,"type":38},"2026-05-15","ACTUAL",{"date":40,"type":38},"2026-03-31",{"date":42,"type":21},"2029-09-30",{"name":44,"class":45},"Tri-Service General Hospital","OTHER",1,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":5},"100573334","NCT06744933","Auricular Acupressure Integrated With a Smartphone Application for Weight Reduction","Self-administered Auricular Acupressure Integrated With a Smartphone Application for Weight Reduction in Patients With Obesity Accompanied With Obesity-related Comorbid Illness: A Randomised Controlled Clinical Trial","Inclusion Criteria:\n\n1. age ≥ 18 years;\n2. Body Mass Index (BMI) ≥ 30 kg\u002Fm2 and \u002For abdominal obesity (i.e., central obesity), that is, male waist circumference ≥ 90cm while female waist circumference ≥ 80cm;\n3. fulfils diagnostic criteria for metabolic syndrome with any two or more of the following: (a) blood pressure ≥ 130\u002F85 mmHg and\u002F or confirmed diagnosis of hypertension with treatment; (b) fasting blood glucose ≥ 100 mg\u002Fdl (5.6 mmol\u002FL) and\u002F or confirmed diagnosis of diabetes with treatment; (c) fasting triglyceride ≥ 150 mg\u002Fdl (1.7 mmol\u002FL) and\u002F or received specific treatment on dyslipidaemia; (d) fasting high-density lipoprotein (HDL) \\\u003C 40mg\u002Fdl (\\\u003C 1.03mmol\u002FL) in male; \\\u003C 50mg\u002Fdl (\\\u003C 1.29 mmol\u002FL) and\u002F or received specific treatment on dyslipidaemia; These standards are based on the diagnostic criteria for metabolic syndrome from the World Health Organisation (1999), the International Diabetes Federation Criteria (2005), and the Chinese Diabetes Society (2000);\n4. are taking medications and receiving follow-up medical consultation \\[Note: With the consent of the participants, the researchers (i.e., the RCA and the RA) will verify relevant medical records in the follow-up appointments\\];\n5. taken no weight control measures in the past 6 months;\n6. has no trauma, inflammation or pathological lesion on ears;\n7. is a smartphone user.\n\nExclusion Criteria:\n\n1. has any eating disorder (screened by the 5-item SCOFF questionnaire);\n2. has drug-induced obesity;\n3. is pregnant;\n4. has cognitive impairment (Abbreviated Mental Test (Hong Kong version), AMT score below 6 (less than or equal to 5) will be excluded.);\n5. has cancer; or\n6. has a severe body disability, such as hemiplegia, that may prevent following instructions to use the smartphone.\n7. is planning to have weight-reduction treatment(s) (such as medications targeted for weight reduction, and bariatric surgery) in the coming 6 months.\n8. is taking the following medications that potentially affect the body weight:\n\n   * Corticosteroids (e.g., prednisone and dexamethasone)\n   * Second generation antipsychotics (e.g., olanzapine, clozapine, quetiapine and risperidone)\n   * Levothyroxine\n   * FDA-approved medications for obesity or weight loss (e.g., phentermine, diethylpropion, phendimetrazine, phentermine + topiramate extended release (ER), naltrexone + bupropion ER, orlistat, liraglutide, semaglutide and GLP-1 (liraglutide\u002F semaglutide) + tirzepatide)","18 Years",{"count":55,"type":21},220,[24],"The goal of this clinical trial is to learn whether self-administered auricular acupressure integrated with a smartphone application works to reduce weight in patients with obesity accompanied with obesity-related comorbid illness. The main questions it aims to answer are:\n\n* Is there significant difference in the Body Mass Index (BMI) between the self-administered auricular acupressure integrated with a smartphone app (Version 2) group (experimental group) and the usual care group, in people with obesity accompanied with metabolic syndrome?\n* Are there significant differences in other anthropometric parameters between the two groups? These parameters include waist circumference, body fat percentage, skeletal muscle percentage, and waist-to-hip ratio.\n* Are there any significant differences in obesity-related parameters between the two groups? These parameters include blood lipid profile (triglyceride, total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)), blood glucose concentrations (fasting glucose and glycated haemoglobin\u002F HbA1c), and blood pressure.\n\nParticipants in the experimental group will:\n\n* Be affixed with 6 to 8 hypoallergic Vaccariae Semen ear patches on one ear each time\n* Visit the clinic twice a week to change a new set of ear patches on the opposite ear\n* Will undergo this intervention for 8 weeks\n* Install a smartphone application which will send pop-up notifications to remind them to press on the ear patches regularly every day\n* Keep a record on the number of times pressing on the smartphone application",[27],[60,61,62,31,32,63,64,65,66,67,68,69],"auricular acupressure","auricular therapy","weight reduction","mobile health","mHealth","smartphone application","traditional Chinese medicine","TCM","ear acupressure","weight loss","NOT_YET_RECRUITING","2025-04-07",{"date":73,"type":38},"2025-04-09",{"date":73,"type":21},{"date":76,"type":21},"2026-12-31",{"name":78,"class":45},"Tung Wah College",""]